Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Genet Med
; 26(7): 101138, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38602181
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligopeptides
/
Barth Syndrome
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Genet Med
Journal subject:
GENETICA MEDICA
Year:
2024
Document type:
Article
Affiliation country:
Moldova
Country of publication:
United States